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Abstract
Background French clinical recommendations suggest
prescribing long-acting injectable (LAI) antipsychotics to
patients with a maintenance treatment indication in
schizophrenia. Despite this, and due to their relatively high
acquisition and administration costs, LAIs are still under-
used in clinical practice in France, thus highlighting the
need for pharmacoeconomic evaluations.
Objective Our objective was to estimate the cost effec-
tiveness of paliperidone LAI (or paliperidone palmitate),
a once-monthly second-generation LAI antipsychotic,
compared with the most common antipsychotic medica-
tions for the maintenance treatment of schizophrenia in
France.
Methods A Markov model was developed to simulate the
progression of a cohort of schizophrenic patients through
four health states (stable treated, stable non-treated, relapse
and death) and to consider up to three lines of treatment to
account for changes in treatment management. Paliperi-
done LAI was compared with risperidone LAI, aripiprazole
LAI, olanzapine LAI, haloperidol LAI (or haloperidol
decanoate) and oral olanzapine. Costs, quality-adjusted
life-years (QALYs) and number of relapses were assessed
over 5 years based on 3-month cycles with a discount rate
of 4 % and from a French health insurance perspective.
Patients were considered to be stabilised after a schizo-
phrenic episode and would enter the model at an initiation
phase, followed by a prevention of relapse phase if suc-
cessful. Data (e.g. relapse or discontinuation rates) for the
initiation phase came from randomised clinical trials,
whereas relapse rates in the prevention phase were derived
from hospitalisation risks based on real-life French data to
capture adherence effects. Safety and utility data were
derived from international publications. Additionally, costs
were retrieved from French health insurance databases and
publications. Finally, expert opinion was used for valida-
tion purposes or in case of gaps in data. The robustness of
results was assessed through deterministic and probabilistic
sensitivity analyses.
Results All LAI antipsychotics were found to have similar
costs over 5 years: approximatively €55,000, except for
paliperidone LAI which had a discounted cost of €50,880.
Oral olanzapine was less costly than LAIs (i.e. €50,379 after
5 years) but was associated with fewer QALYs gained and
relapses avoided. Paliperidone LAI dominated aripiprazole
LAI, olanzapine LAI and haloperidol LAI in terms of costs
per QALY, and it was associated with slightly fewer
QALYs when compared with risperidone LAI (i.e. 3.763 vs
3.764). This resulted in a high incremental cost-effective-
ness ratio (ICER) (i.e. €4,770,018 per QALY gained) for
risperidone LAI compared with paliperidone LAI.
Paliperidone LAI was more costly than olanzapine oral but
associated with more QALYs (i.e. ICER of €2411 per
QALY gained for paliperidone LAI compared with oral
olanzapine). Paliperidone LAI had a probability of being
the optimal strategy in more than 50 % of cases for a
willingness-to-pay threshold of €8000 per QALY gained.
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Conclusion This analysis, to the best of our knowledge, is
the first of its kind to assess the cost effectiveness of
antipsychotics based on French observational data.
Paliperidone LAI appeared to be a cost-effective option in
the treatment of schizophrenia from the French health
insurance perspective.
Key Points for Decision Makers
Risperidone long-acting injectable (LAI) and
paliperidone LAI were associated with the most
discounted quality-adjusted life-years (QALYs) over
5 years (i.e. 3.764 and 3.763, respectively), with
paliperidone LAI less costly than risperidone LAI,
resulting in an incremental cost-effectiveness ratio
(ICER) of €4,770,018 per QALY gained for
risperidone LAI compared with paliperidone LAI.
Paliperidone LAI dominated aripiprazole LAI,
olanzapine LAI and haloperidol LAI, and was
associated with an ICER of €2411 per QALY gained
compared with olanzapine oral.
In the probabilistic sensitivity analysis, for any
threshold, paliperidone LAI was associated with the
highest probability of being the optimal strategy in
comparison with all other strategies simultaneously
in terms of QALYs gained and relapses avoided.
The present analysis suggests that paliperidone LAI
is a cost-effective treatment for patients with
schizophrenia in France. However, the study also
highlights the scarcity of available data, especially
on long-term efficacy.
1 Introduction
Schizophrenia is a severe mental disorder characterised by
deep disruptions in thinking, language, perception, and
sense of self [1]. The various symptoms can be classified
into two main categories: ‘positive’ symptoms (such as
delusions, hallucinations, disorganized speech and cata-
tonic behaviour) and ‘negative’ symptoms (such as blunted
affect and alogia) [2, 3]. The course of the disease varies
widely and, in the majority of cases, patients experience
alternating periods of remission and recurrence, with
unpredictable patterns of symptoms [4, 5]. The pathology
leads to a decrease in functional capacity [6], and is
associated with a broad range of psychosocial difficulties
such as unemployment, loneliness and housing issues [7].
All of the above substantially affect quality of life and
wellbeing. Those with schizophrenia face a mortality risk
that is more than double that of the general population, a
statistic that is predominantly due to the high rate of sui-
cides, cardiovascular diseases, and metabolic and infec-
tious afflications [1].
According to the World Health Organization (WHO),
schizophrenia is one of the most concerning pathologies of
the twenty-first century, affecting more than 21 million
people worldwide, and ranks as the 14th cause of disability
in the world [8, 9]. In France, schizophrenia is estimated to
affect between 300,000 and 600,000 people, with an inci-
dence of 10,000 new patients per year [10–12]. The public
health and financial burdens of schizophrenia are recog-
nised to be substantial by the French authorities (e.g.
patients affected by schizophrenia represent the largest
group of hospitalised patients in public institutions and
specialised centres in France) [3, 7, 13–15]. According to
the French Ministry of Health, improvement in the
healthcare management of patients with mental disorders,
and especially the prevention and reduction of the risk of
relapse through the enhancement of patient follow-up and
quality of life, is a major public health concern [9].
Despite the increase in interest in the management of
schizophrenia, information regarding the current treatment
landscape remains unclear. The lack of treatment compliance
is an area of concern that can be difficult to accurately
quantify. Long-term clinical trials may include biases in terms
of observance due to reinforced monitoring and close man-
agement of the patients inherent to the protocol. Although
observational studies are often more apt to reflect the beha-
viour of patients in a real-life setting, data are limited.
Moreover, the superiority of second-generation versus
first-generation antipsychotics has not been clearly
demonstrated as part of clinical trials and is still a con-
troversial topic [16–18]. Given this, in 2011, the French
National Health Agency (Haute Autorite´ de Sante´ [HAS])
decided to re-evaluate the safety and efficacy of second-
generation oral antipsychotics compared with the first-
generation variants [19]. The HAS and most evidence-
based guidelines for the maintenance treatment of
schizophrenia recommend long-acting injectable (LAI)
antipsychotics to be used predominantly in the prevention
of relapse for non-compliant patients. Some consensus-
based guidelines recommend the use of LAIs as a first-line
treatment for most patients who require long-term
antipsychotics [20, 21]. Furthermore, the difference in
clinical and economic benefits between oral and LAI forms
have not yet been clearly established [22, 23].
Few economic studies have been conducted in France
assessing either the costs associated with schizophrenia or
the benefit/costs ratio of antipsychotics [24, 25]. In 2005, a
French study comparing three antipsychotics established
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superiority with LAI risperidone compared with LAI
haloperidol and oral olanzapine [25]. Since 2005, three
LAI antipsychotics have received a European marketing
authorisation (MA): olanzapine LAI (Zypadhera, MA in
2008), paliperidone LAI (Xeplion, MA in 2011) and
aripiprazole LAI (Abilify Maintena, MA in 2013). To our
knowledge, no recently published studies have compared
the cost impact and health benefits of these treatments in
France.
Using an original pharmacoeconomic model and real-
life French data on hospitalisation [26], we sought to assess
the cost effectiveness of the most relevant pharmaceutical
maintenance treatment options in the management of
schizophrenia in France for patients stabilised after a
schizophrenic episode.
2 Materials and Methods
2.1 Overview
A model was developed following the French HAS
guidelines for health economic studies (see Appendix
Table 9) [27]. Second-generation LAI antipsychotics
approved in France, most prescribed first-generation LAIs
and oral second-generation antipsychotics were identified
and validated by clinical experts.1,2 These included
paliperidone LAI, risperidone LAI, aripiprazole LAI,
olanzapine LAI, haloperidol LAI and oral olanzapine.
Costs, quality-adjusted life-years (QALYs) gained and
relapses avoided were assessed and compared for each of
these compounds over a time horizon of 5 years at a dis-
count rate of 4 %, from a French statutory health insurance
perspective (‘Assurance Maladie’ [25]).
An health economic expert validated the approach by
ensuring that the methodology aligned with French
guidelines, international guidelines and economic theory.3
Relapse rates were derived from hospitalisation risks
from a French observational study: the CGS (Cohort for the
General study of Schizophrenia) [26]. The patient pathway
for each assessed treatment in the model was split into two
main steps (Fig. 1) to account for changes in healthcare
management between the initiation and prevention phases
of the treatment (e.g. difference in antipsychotic doses,
frequency of clinicians’ consultations, hospitalisation
duration for initiation, occurrence of adverse events, etc.).
2.2 Markov Model
In order to conserve enough flexibility while retaining a
certain level of transparency, and based on previous pub-
lished cost-effectiveness analyses of antipsychotics [23, 28,
29], an original Markov model structure was developed for
our study. The robustness of the conclusions was tested in
sensitivity analyses, and the results were compared with the
published literature. This approach has been deemed
appropriate for chronic diseases such as schizophrenia
because it facilitates the modelling of recurrent events such
as relapses. The model allowed the comparison of all
interventions simultaneously, considering specific initia-
tion phases for each of the comparators. The core model
was run based on data for treatment efficacy and discon-
tinuation rates, while sub-models ran in parallel, tracking
adverse event occurrences (one sub-model by type of
adverse event).
The Markov model simulated the progression of a
cohort of adult schizophrenic patients, stabilised after a
schizophrenic episode, through four main health states
(‘stable treated’, ‘stable non-treated’, ‘relapse’ and ‘death’)
and up to three lines of treatment over 5 years (Fig. 1). The
model was developed using Microsoft Excel, version
2010 (Microsoft Corporation, Redmont, WA, USA).
According to clinical opinion1, a cycle length of
3 months was considered appropriate to capture both
clinical practice and the associated events such as relapses
and adverse events. Patients entered the model after a
1-month stabilisation phase and initiated antipsychotic
treatment at a specific dose (i.e. the initiation phase, shown
in blue in Fig. 1). Stable patients who continue to receive
the same therapy after the 3-month initiation phase pro-
gress to the prevention phase (i.e. in white in Fig. 1),
otherwise patients discontinue treatment.
Over the prevention phase, patients could either progress
to another health state because of a treatment discontinu-
ation or remain in the same state. Three causes of treatment
discontinuation were considered: (1) patients who relapsed
due to lack of efficacy and progression to the ‘relapse’
health state (with or without a hospitalisation), (2) patients
who switched due to medication intolerance and moved to
the ‘stable treated’ health state in the initiation phase on the
next line of antipsychotics, or (3) patients who interrupted
their antipsychotic treatment based on personal choice,
were lost to follow-up or other reasons, and transitioned to
the ‘stable non-treated’ health state. At each cycle, patients
could move to the health state ‘death’ from any state.
2.3 Therapeutic Sequence
The treatment sequence consisted of three lines of antipsy-
chotics (Fig. 2). In accordance with French guidelines [30],
1 Pr Christophe Lanc¸on (Faculty of Medicine of Marseille, Marseille,
France) and Dr Ludovic Samalin (CHU Clermont-Ferrand, Clermont-
Ferrand, France).
2 Please note that each time the expert’s opinion is mentioned, we
refer to the experts reported in footnote 1 and/or 3.
3 Pr Pierre Le´vy (University of Paris-Dauphine, Paris, France).
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which recommend second-generation LAI antipsychotics as
the first-line maintenance treatment for patients with
schizophrenia, patients in the model could receive any of the
four second-generation LAIs licensed in France (i.e.
paliperidone LAI, risperidone LAI, aripiprazole LAI and
olanzapine LAI) [31–34]. To compare these with other
classes of antipsychotics still available on the French mar-
ket, we also included the most prescribed typical LAI and
oral antipsychotic (haloperidol LAI, 42 % of the typical
LAIs in France [26, 35]; and olanzapine oral, 31 % of oral
antipsychotics in France [26, 36]). As the objective was to
assess the cost effectiveness of initial treatment, subsequent
treatment lines were assumed to be independent of the initial
line and similar across assessed treatments. Based both on
French clinical guidelines [30] and on expert opinion, the
second-line treatment included second-generation LAI
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Fig. 1 Markov model structure.
The CGS (Cohort for the
General study of Schizophrenia)
is a French observational study
that aimed to compare the
impacts of risperidone LAI with
other antipsychotics in terms of
hospitalisation rates. At each
cycle, patients could move to
the health state ‘death’ from any





Fig. 2 The treatment sequence. ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, OLAI olanzapine long-acting
injectable, OO oral olanzapine, PLAI paliperidone long-acting injectable, RLAI risperidone long-acting injectable
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antipsychotics. Thus, clinical and economic inputs were
elicited by a weighted average in equal proportions of data
for paliperidone LAI (25 %), risperidone LAI (25 %),
aripiprazole LAI (25 %) and olanzapine LAI (25 %).
Clozapine was prescribed as the last treatment line accord-
ing to international clinical guidelines4 [37].
The antipsychotic doses were as per Summary of Pro-
duct Characteristics (SmPC) recommendations (Table 1).
2.4 Model Parameters and Assumptions
Input parameters were derived from an observational study
(i.e. CGS) [26], clinical trials [38, 39], relevant literature
[40, 41] and assumptions based on expert opinions. We
conducted a literature review (until 2014) through
MEDLINE and MEDLINE-In-Process databases,
focusing on meta-analyses results for efficacy, safety and
discontinuation rates for the different comparators. Rele-
vant terms for the pathology were combined with appro-
priate study types, interventions and outcomes. The
electronic search was restricted to English and French
publications. Additional ad hoc searches were conducted to
complete information on standardised mortality rate (SMR)
by health state and utility, as well as hospitalisation costs,
treatment costs and treatment-related adverse event costs in
France (with an update for treatment costs in 2015). When
data were lacking from published literature, expert opinion
was sought through advisory panels and questionnaires.
2.4.1 Demographic Characteristics
Demographic characteristics were based on the CGS [26],
where 68 % of patients were male and the mean age was
38 years.
The CGS aimed to compare risperidone LAI with other
antipsychotics and the impact on hospitalisation rates in
real-life settings in France [26]. This study followed 1859
patients diagnosed with schizophrenia over a mean period
of 12 months and found that patients treated with risperi-
done LAI had lower rates of hospitalisation than those
receiving other antipsychotics.
2.4.2 Transition Probabilities
In the initiation phase, transition probabilities were derived
from the phase III clinical trial PSY-3006 assessing the
efficacy and safety of paliperidone LAI versus risperidone
LAI over 13 weeks (i.e. patient follow-up and monitoring
environment closer to trial conditions) [39]. Following
clinical opinion, we applied the assumption that the relative
risk of treatment discontinuation in the initial phase was
comparable between oral and injectable forms; for other
injectable antipsychotics (i.e. aripiprazole LAI, olanzapine
LAI and haloperidol LAI), odds ratios (ORs) from the
meta-analysis by Leucht et al. [40] were derived from the
oral forms (calculation detailed in Table 2). It was assumed
that the risk of relapse, switch and interruption for oral
olanzapine was similar to those for olanzapine LAI in the
initiation phase (i.e. noninferiority analyses showed com-
parable efficacy between oral and LAI in the initiation
phase, in which the close follow up of patients ensures a
certain level of compliance irrespective of treatment form)
[42–44].
In the prevention phase, the risks of relapse were derived
from real-life data (i.e. CGS; data allowing the capture of
adherence effects) when available [26]. The hospitalisation
rate from the CGS was chosen to estimate the relapse rate
based on the conclusion from Olivares et al. [45], who
demonstrated that hospitalisation was the most frequently
used factor to track the incidence of relapse. In the CGS, the
annual risk of hospitalisation, readjusted for treatment
Table 1 Mean doses of
antipsychotics used in the model
Initiation phase Prevention phase Sources
PLAI 150 mg on D1; 100 mg on D8 75 mg monthly Xeplion SmPC [32]
RLAI 37.5 mg/2 weeksa 37.5 mg/2 weeks RisperdalConsta SmPC [31]
ALAI 400 mg monthly 400 mg monthly Abilify Maintena SmPC [34]
OLAI 300 mg/2 weeks 210 mg/2 weeks Zypadhera SmPC [33]
HLAI 5 ml per injection 5 ml per injection Haldol Decanoas SmPC [35]
OO 10 mg/day 10 mg/day Zyprexa SmPC [36]
Clozapine 300 mg/day 300 mg/day Clozapine SmPC [54]
ALAI aripiprazole long-acting injectable, Dx day x, HLAI Haloperidol long-acting injectable, OLAI olan-
zapine long-acting injectable, OO oral olanzapine, PLAI paliperidone long-acting injectable, RLAI
risperidone long-acting injectable, SmPC summary of product characteristics
a The recommended dose of RLAI was 25 mg in the SmPC, but the equivalent dose to be compared with
paliperidone LAI was 37.5 mg. We decided, based on clinical expert opinion, to use risperidone LAI at
37.5 mg/2 weeks in the analyses
4 Related to treatment-resistant schizophrenia: ‘‘Strongly consider
clozapine after two unsuccessful antipsychotic trials’’ (Stahl et al
[37]).
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effects and hospitalisation history associated with risperi-
done LAI, was 19.43 %5 (assuming two-thirds of relapsing
patients were hospitalised6 [25, 28], resulting in an annual
risk of relapse of 29.15 %). Thus, the 3-monthly risk of
relapse for patients treated with risperidone LAI was esti-
mated at 8.25 % in the model. In case of relapse requiring
hospitalisation, the probabilities of leaving the hospital were
time dependent and were derived from real-life data from
the CHU Clermont-Ferrand [46]. Finally, in the prevention
phase, the probability of discontinuation due to treatment
interruption and lack of tolerance was derived from the
intent-to-treat (ITT) population in the clinical trial PSY-
3001 (calculation detailed in Table 2), assessing paliperi-
done LAI over 52 weeks [38]. This study aimed to evaluate
the efficacy and tolerability of paliperidone LAI in delaying
‘time to relapse’ in adults with schizophrenia.
2.4.3 Clinical Assumptions
We assumed that, after a relapse, two-thirds of patients
were managed in a hospital setting whilst the remainder
were treated in an outpatient care setting. This assumption
was based on the recommendations of clinical experts.
Patients were not allowed to move from the ‘relapse
Table 2 Three-month probabilities of treatment discontinuation (i.e. relapse, switch and interruption)
Items PLAI RLAI ALAI OLAI HLAI OO Clozapine Sources
3-month probability of relapsea
IP 0.0659 [39] 0.0701 [39] 0.0820 [40] 0.0640 [40] 0.1052 [40] 0.0640d [40] 0.1158e RCT for PLAI and RLAI [39], and
meta-analysis for other
comparators [40]
PP 0.0825f 0.0825 [26] 0.0825f 0.0825f 0.1810 [26] 0.1532 [26] 0.1158 [72] Observational data for all
comparators [26], meta-analysis
vs. OO for clozapine [72]
3-month probability of switchb
IP 0.0329 [39] 0.0163 [39] 0.0413 [40] 0.0320 [40] 0.0537 [40] 0.0320d 0.0048e RCT for PLAI and RLAI [39], and
meta-analysis for other
comparators [40]
PP 0.0042 [38] 0.0042g 0.0042g 0.0042g 0.0042g 0.0042g 0.0048 [72] RCT for PLAI [38], meta-analysis
vs. OO for clozapine [72]
3-month probability of interruptionc
IP 0.1450 [39] 0.1452 [39] 0.1767 [40] 0.1412 [40] 0.2203 [40] 0.1412d 0.0230e RCT for PLAI and RLAI [39], and
meta-analysis for other
comparators [40]
PP 0.0387 [38] 0.0387g 0.0387g 0.0387g 0.0387g 0.0387g 0.0230 [72] Hough et al. [38]
Haro et al. [72]
Formula applied for probabilities derived from OR: pXLAI ¼ pPLAI
1
ORð Þ
1pPLAIð Þþ pPLAI 1OR
  
ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, IP Initiation phase, OLAI olanzapine long-acting injectable,
OO oral olanzapine, OR odds ratio, PLAI paliperidone long-acting injectable, PP prevention phase, RCT randomised controlled trial, RLAI
risperidone long-acting injectable, SmPC summary of product characteristics
a Due to lack of efficacy
b Due to lack of tolerance
c Due to patient choice, loss to follow-up and other reasons
d Assumed equal to olanzapine LAI
e Probabilities assumed to be similar for clozapine in initiation and in prevention phase
f Assumed equal to risperidone LAI
g Assumed equal to paliperidone LAI
5 Based on a global hospitalisation rate of 53/100 patient-years
readjusted according to the hospitalisation history (i.e. OR 2.97
between risperidone LAI and other antipsychotics) and a relative
annual risk of hospitalisation of risperidone LAI versus other
antipsychotics of 0.66, the readjusted hospitalisation rate for risperi-
done LAI was 44.3/100 patient-years. This rate was then divided by
the annual average number of hospitalisations (i.e. 2.05/year). Finally,
the annual risk of hospitalisation was derived based on the propor-
tional hazard assumption (i.e. risk = 1 - exp [‘ratetime’]).
6 Based on Llorca et al. 2005 [25], in which it was assumed that 60 %
of French patients had a complete hospitalisation in case of lack of
response, and Mehnert et al. 2012 [28], in which it was assumed that
63 % of patients who had relapsed had been admitted to hospital
during the 6-month observation period.
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requiring a hospitalisation’ state to ‘relapse without hos-
pitalisation’ or vice versa. Based on the mean interruption
rates reported in PSY-3006 (i.e. patient’s choice, lost to
follow-up and other reasons [38]), we assumed that the
proportion of patients who restarted the same antipsychotic
after a relapse was 15 %. We also assumed that patients
initiated their new antipsychotic treatment during the
relapse phase (i.e. either at the hospital or in the outpatient
setting) and then progressed directly to the prevention
phase in the health state ‘stable treated’.
Product labelling recommended LAI antipsychotics for
previously stable patients [31–35]. In an international
naturalistic study (RODOS [risperidone olanzapine drug
outcomes studies in schizophrenia]) that included 1901
patients with schizophrenia, 548 of whom were from
French centres and who received either olanzapine or
risperidone, the median time to discharge from hospital for
patients receiving risperidone and olanzapine was esti-
mated to be 32 days and 37 days, respectively (with an
average adjusted number of days at hospital of 27.3 and
31.3, respectively) [47]. Thus, all patients in relapse had a
1-month stabilisation phase followed by an additional
period of hospitalisation specific for each new antipsy-
chotic (which was similar in the initiation phase). LAI
antipsychotics without oral supplementation (i.e. paliperi-
done LAI, olanzapine LAI and haloperidol LAI) were
associated with an additional week of hospitalisation to
finalise the treatment initiation. Patients initiating an LAI
antipsychotic with an oral supplementation were assumed
to stay at the hospital until the end of their supplementation
phase (i.e. 2 additional weeks for risperidone LAI and
aripiprazole LAI). Patients who were initiated with an oral
antipsychotic (i.e. olanzapine oral and clozapine) had a
stabilisation phase of 1 month (i.e. assume no additional
time of hospitalisation to initiate the treatment, based on
clinical opinion). In the case of relapse without hospitali-
sation, it was assumed that outpatients remained in relapse
for 1 month, based on the duration of relapse without
hospitalisation estimated at 30 days by Mehnert et al. [28],
thus 100 % of patients moved after 3 months [28].
When patients switched due to drug intolerance, the next
antipsychotic was initiated at the hospital in 10 % of cases
and in outpatient care for the others. Based on expert
opinion, clozapine was initiated within a hospital setting
for 90 % of cases.
All patients who interrupted their treatment and did not
relapse after one cycle were assumed to remain
stable without treatment (one-third of patients), reinitiate
the same antipsychotic (one-third of patients) or move to
the next line of therapy in the initiation phase (one-third of
patients). Based on expert opinion, we assumed a similar
rate of treatment interruption for the other LAI
antipsychotics of interest and that olanzapine oral was
equivalent to olanzapine LAI (Table 2) [43].
2.4.4 Mortality Rates
Different probabilities of death were applied to stable pa-
tients and to patients in relapse. Mortality rates for
stable patients were derived from a meta-analysis based on
37 studies over 25 countries, including France [48–50]. The
median SMR for all-cause mortality in schizophrenia was
2.58 (3.02 for men and 2.37 for women) and was used in
the model for stable patients. Mortality rates applied to
patients in relapse were derived from SMR values in the
year following hospital discharge from real-life data from
patients with a principal diagnosis of schizophrenia from
an English hospital (i.e. SMR 6.2) [51].
2.4.5 Adverse Events
Four adverse events were included in the study:
extrapyramidal symptoms (EPS), tardive dyskinesia (TD),
weight gain (WG) and diabetes. These adverse events were
identified by experts as both clinically and economically
relevant. Adverse events were considered individually, and
each adverse event was assigned a specific duration: i.e.
TD, WG and diabetes were assumed to be permanent
within the time horizon (5 years), whereas the duration of
EPS was assumed to be 3 months (one cycle), based on
expert opinion. Permanent adverse events of interest were
counted cumulatively. Patients with EPS were assumed to
have the same probability of experiencing EPS at each
cycle, regardless of treatment phase (Table 3). We
assumed the safety profile of oral forms was similar to that
for LAI forms [43].
2.4.6 Utility
The HAS recommends the use of French empirical data of
preference scores but allows data from other countries if
none are available in the French context [27]. Utility data
were derived from a British study based on a time trade-off
technique conducted in 49 stable patients with
schizophrenia and 75 lay persons [41]. Health state utilities
and utility decrement associated with side effects are pre-
sented in Table 4.
2.4.7 Costs and Resource Utilisation
Resource unit costs were expressed in €, December 2014
values. All costs were adjusted when necessary using the
consumer price index (CPI) for health goods and services
up to December 2014 [52].
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2.4.7.1 Costs of Antipsychotic Medication Schizophrenia
is a chronic long-term illness, therefore treatment costs of
schizophrenia are reimbursed at 100 % by the statutory
health insurance (SHI) in France [12]. Costs were based on
the lowest public daily price with all taxes included and are
published on the SHI website [53], with respect to the
doses recommended by the SmPC [31–36, 54]. Generic
drugs were used when available (Table 5). We assumed
that, when patients were hospitalised, the antipsychotic
medication costs were included in the daily hospitalisation
costs, so no additional treatment costs were applied during
the hospitalisation time. The treatment costs associated




Phase PLAI (%) RLAI (%) ALAI (%) OLAI (%) HLAI (%) OO (%) Clozapine
(%)
Sources
EPS IP 5.50 [32] 5.50 [31] 3.53 [16] 3.21 [16] 13.28 [16] 3.21 [16] 0.98 [16] SmPC for PLAI [32] and
RLAI [31], meta-analysis
for others [16]
PP 5.50 [32] 5.50 [31] 3.53 [16] 3.21 [16] 13.28 [16] 3.21 [16] 0.98 [16] Similar to the initiation phase
TD IP 0.17 [39] 0.16 [39] 0.17b 0.00c 2.28 [17] 0.00 [17] 0.00c RCTs [17, 39]
PP 0.00 [73] 0.00 [31]b 0.00 [34]b 0.00 [33]b 1.00 [35] 0.00 [36]b 0.00c RCT for PLAI [73], SmPC
and assumptions for others
[31,33–36]
WG IP 5.50 [32] 5.50 [31] 5.50 [34] 46.80 [33, 74] 5.50 [35] 46.80d 5.50 [54] RCTs for OLAI [74], SmPC
for others [31, 32, 34, 35,
54]
PP 1.47 [38] 1.47b 1.47b 10 [33] 7.24 [35,
72]
10 [36] 8.01 [72] RCT [38] for PLAI, meta-
analysis for HLAI and
clozapine [72], SmPC for
others [33, 36]
Diabetes IP 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Hypothesis: no diabetes in
instauration phase
PP 0.55 [32] 0.55 [31] 1.00 [34] 0.61 [33]c 0.47 [75] 0.61 [75] 0.00 [54] Meta-analysis for HLAI and
OO [75], SmPC for others
[31, 32, 34, 54]
ALAI aripiprazole long-acting injectable, EPS extrapyramidal symptoms, HLAI haloperidol long-acting injectable, IP initiation phase, OLAI
olanzapine long-acting injectable, OO oral olanzapine, PLAI paliperidone long-acting injectable, PP prevention phase, RCT randomised con-
trolled trial, RLAI risperidone long-acting injectable, SmPC summary of product characteristics, TD tardive dyskinesia, WG weight gain
a When available, the risk of adverse events was derived from the SmPC, using the average value between the bounds of the provided interval;
e.g. EPSPLAI = (1 % ? 10 %)/2 = 5.5 %). In a conservative approach, the risk of diabetes for aripiprazole LAI was based on the inferior bound
of the interval; i.e. 1 %
b Assumed equal to paliperidone LAI
c Assumed equal to olanzapine oral
d Assumed equal to olanzapine LAI
Table 4 Utility by health states
and utility decrements
associated with adverse events
Health states Mean utility Sources
Health state utility
Stable (no side effects) 0.919 Briggs et al. [41]
Relapse (not requiring hospitalisation) 0.762 Mid-point between utilities for stable
and relapse (requiring hospitalisation)
Relapse (requiring hospitalisation) 0.604 Briggs et al. [41]
Dead 0.000
Utility decrement associated with adverse events
Extrapyramidal symptom -0.197 Briggs et al. [41]
Tardive dyskinesia -0.197 Assumed similar to extrapyramidal symptom
Weight gain -0.094 Briggs et al. [41]
Diabetes -0.150 Briggs et al. [41]
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with second-line treatments were computed as the weigh-
ted average costs of the four LAIs included in the model
(25 % of aripiprazole LAI, 25 % of olanzapine LAI, 25 %
of paliperidone LAI and 25 % of risperidone LAI). Thus,
the costs of antipsychotics for one cycle of second-line
treatment was set at €611 for patients who started at the
hospital (i.e. corresponding to the period after the discharge
from the hospital), and €1059 where patients were assumed
to start in ambulatory care. The medication costs for one
cycle of second-line treatment in the prevention phase was
assumed to be equal to €913.
2.4.7.2 Administration Costs LAI antipsychotic injec-
tions were administered by a nurse. The tariff of an
injection was €7 according to the SHI [55].
2.4.7.3 Maintenance Costs of Schizophrenia The main-
tenance cost of schizophrenia was considered to be €1062
per year, per patient. This was based on the annual mean
cost of outpatient care for a patient with schizophrenia
from the SHI perspective [56]. We assumed the mainte-
nance cost was similar for all comparators and reflected
stable patients without adverse events. Additional costs
were added for adverse events and medicines.
2.4.7.4 Costs of Hospitalisation We assumed the cost of
initiation to be based on the daily cost of hospitalisation for
patients initiating their antipsychotic treatment in the hos-
pital. The hospitalisation cost in a psychiatric unit was
estimated in a report by the Court of Auditors at €450 per
day in 2011 (i.e. €450 9 99.6/102.6 [i.e. CPI 2014/CPI
2012] = €436.84 in December 2014) [57]. A lower cost
was identified by Raymond et al. [24], with a daily hos-
pitalisation cost at €288.30 in 2009 (i.e. €288.30 9 99.6/
103.4 [i.e. CPI 2014/CPI 2009] = €277.70 in December
2014) and was assessed in an extra scenario [24].





Unit price (€) Cost per 3 months (€)b Comments/sources [31–36, 38]
PLAI 150 mg 456.50 1 456.50 [76] Inpatientc: 501
Outpatient: 1265
Prevention phase: 752
Initiation phase: PLAI 150 mg at
D1, 100 mg at D8, 75 mg/month
Prevention phase: 75 mg/month
PLAI 100 mg 306.87 1 306.87 [77]
PLAI 75 mg 250.73 1 250.73 [78]
RLAI 37.5 mg/2 ml 130.86 1 130.86 [79] Inpatientc: 530
Outpatient: 806
Prevention phase: 785
Initiation and prevention phase:
37.5 mg biweekly (equivalent to
75 mg of PLAI monthly)
Note: 2-week oral supplementation
during the initiation phase
Oral risperidone 4 mg 29.77 30 0.99 [80]
ALAI 400 mg 268.51 1 268.51 [81] Inpatientc: 537
Outpatient: 853
Prevention phase: 806
Oral aripiprazole 95.92 28 3.43 [82] Oral aripiprazole: 15 mg/day
OLAI 218.42 1 NA Inpatientc: 874
Outpatient: 1311
Prevention phase: 1311
Only at the hospital. Hypothesis:
half-day hospitalisation cost
OO 43.78 28 1.56 [83] Inpatientc: 874
Outpatient: 14
Prevention phase: 141
OO: 10 mg per day




Clozapine 16.08 28 0.57 [85] Outpatient: 155
Prevention phase: 155
Maximum 300 mg per day
ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, OLAI olanzapine long-acting injectable, OO oral olanzapine,
PLAI paliperidone long-acting injectable, RLAI risperidone long-acting injectable
a Public price all taxes
b Cost per 3 months reflecting when the initiation phase started
c The inpatient initiation phase includes a period at the hospital and an outpatient setting period after discharge. The reported price is the price of
the outpatient setting period only (i.e. 3 months minus the hospitalisation period), since it is assumed that medication costs at hospital were
included in the daily price of hospitalisation (i.e. €436.8)
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2.4.7.5 Cost in Outpatient Setting In the initiation phase
or in case of relapse without hospitalisation, additional
costs were associated with the maintenance cost due to the
increase in psychiatrist visits. Based on expert opinion, it
was assumed that the number of visits for a patient in
relapse was multiplied by three compared with a
stable patient, leading to an additional cost of €222 for
3 months [55].
2.4.7.6 Costs of Managing Adverse Events Additional
costs due to adverse events considered three main items:
medicines, visits and biologic tests. Resources associated
with adverse events, except diabetes, were based on expert
opinion, with tariffs of the SHI applied [58]. A total
average annual cost associated with diabetes management
was derived from a French study and converted to quarterly
costs in the model [59]. Resources and associated costs are
summarised in Table 6.
2.5 Sensitivity Analyses
We conducted sensitivity analyses to explore the impact of
uncertainty associated with the input parameters, as rec-
ommended in the French methodological guide for eco-
nomic evaluations [27]. As this analysis consisted of
multiple comparisons, univariate sensitivity analyses can-
not be presented using tornado diagrams because the costs
and outcomes vary for each strategy. Therefore, we
conducted limited scenario analyses, and the effects of
uncertainty were further explored through probabilistic
sensitivity analyses (PSA). We conducted one-way sensi-
tivity analyses on paliperidone LAI input parameters only
(i.e. a variation of ±15 % was applied based on expert
opinion; see Appendix Table 10 for details) in order to
identify the main drivers of the model. Extra scenarios
were run to test the main assumptions of the model (i.e.
daily hospitalisation costs, hospitalisation duration,
paliperidone LAI dose, utility values in health state ‘Re-
lapse without hospitalisation’ and incidence of diabetes).
Monte Carlo PSAs were performed over 10,000 itera-
tions. The mean duration of stabilisation at the hospital was
drawn from a truncated Normal distribution. Utility inputs
and SMR were estimated using a log-Normal distribution,
for which parameter inputs were based on the mean and
standard deviation. A Beta distribution was applied to
proportions, such as the probabilities of treatment discon-
tinuation (i.e. the proportions of interruption, switch and
relapse), the proportion of relapse requiring hospitalisation,
the proportion of patients treated with the same antipsy-
chotic after a relapse, as well as the proportions of adverse
events based on number of events within a defined popu-
lation. Adverse events based on SmPC and the proportion
of patients initiating their first antipsychotic drug in the
hospital setting were drawn from a Uniform distribution
using minimum and maximum values. To reflect the dif-
ferent treatment options for second-line treatment, the
Table 6 Three-month costs and resources associated with adverse events (2014)
Adverse event Resource items Units and (costs [58]) (€ per 3 months) Sources Global cost (€)




Visits GP: 1 (23.00)
Psychiatrist: 1 (37.00)
Expert opinion
Tests NI (0) Expert opinion
Tardive dyskinesia Medicines NI (0) Expert opinion 97.00




Tests NI (0) –
Diabetes Global (1318.05) Entred study [89] 1318.05
Weight gain Medicines NI (0) – 114.64




Expert opinion and HAS [90]
Tests Blood glucose analyses: 1 (1.4) HAS [90]
Lipid abnormality investigations: 1 (7.3) HAS [90]
GP general practitioner, NI not included
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medication changes were drawn from a Dirichlet distribu-
tion, the parameters of which were derived from expert
opinion. The Dirichlet distribution was also applied to
reflect the transition probabilities for untreated patients and
the proportion of patients in relapse leaving the hospital.
To reflect the uncertainty associated with resource use and
costs and to follow a conservative approach (i.e. equivalent
weight given to each value across the range of the distri-
bution), a triangular distribution of ±50 % (for costs) or
±1 unit (for resources) of the base-case value were applied.
The mean time in relapse was drawn from a Gamma
distribution.
The details of the parameters of the PSA are available in
the technical appendix (Appendix Table 11).
3 Results
3.1 Base Case
Hospitalisation costs represented between 56 and 72 % of
the total undiscounted costs over 5 years (Table 7). As
reported in Table 8, risperidone LAI and paliperidone LAI
generated the highest number of QALYs gained over
5 years as 3.7642 and 3.7634 QALYs, respectively.
Paliperidone LAI was associated with the lowest number of
relapses after olanzapine LAI (1.4366 vs. 1.4333). With
regards to mean costs, oral olanzapine was the least costly
treatment strategy over the 5-year time horizon, with a total
cost of €50,379. Paliperidone LAI was associated with an
incremental cost of €501 over 5 years compared with
olanzapine oral. Olanzapine LAI was the most costly
treatment, with a 5-year total cost of €55,843.
The cost per QALY gained and the cost per relapse
avoided were calculated as incremental cost-effectiveness
measures. In order to compare multiple treatment options,
the results are reported in Table 8, and the efficiency
frontier on the cost-effectiveness plane in terms of QALYs
gained and relapse avoided are presented in Figs. 3 and 4,
respectively. Strategies are first sorted by descending costs
to exclude dominated strategies and strategies subject to
extended dominance (i.e. dominated by a linear combina-
tion of two existing strategies) before calculating the
incremental cost-effectiveness ratios (ICERs) between two
consecutive strategies.
With regards to the cost per QALY gained, paliperidone
LAI dominated aripiprazole LAI, olanzapine LAI and
haloperidol LAI. Paliperidone LAI was associated with an
ICER of €2411 per QALY gained compared with oral
olanzapine.
In terms of cost per avoided relapse, paliperidone LAI
dominated risperidone LAI, aripiprazole LAI and
haloperidol LAI. Paliperidone LAI was associated with an
ICER of €1782 per avoided relapse compared with oral
olanzapine.
3.2 Sensitivity Analyses
3.2.1 One-Way Sensitivity Analyses
The impact of input parameters was tested for paliperidone
LAI. Input parameters that had the greatest impact on the
cost per QALY gained were the probabilities of switch due
to lack of tolerance and rates of adverse events. In terms of
cost per relapse avoided, the one-way sensitivity analyses
showed that probabilities of treatment interruption and
probabilities of relapse due to lack of efficacy as parame-
ters had the highest impact on the ICER.
3.2.2 Extra Scenarios
In the extra scenario associated with using the cost of
hospitalisation from Raymond et al. [24] (i.e. €277.70 in
December 2014), paliperidone LAI remained the least
Table 7 Breakdown costs by health state and total costs, over 5 years (€)










OO 1248 10,848 228 39,450 707 2630 55,113 50,379
PLAI 5112 14,387 239 33,365 639 1628 55,370 50,880
RLAI 8496 14,811 239 33,705 626 1627 59,504 54,952
HLAI 4635 10,779 255 41,576 725 1886 59,857 55,127
ALAI 8597 14,516 250 34,200 629 2052 60,245 55,657
OLAI 5579 17,522 250 33,911 646 2717 60,626 55,843
AE adverse event, ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, OLAI olanzapine long-acting injectable, OO
oral olanzapine, PLAI paliperidone long-acting injectable, RLAI risperidone long-acting injectable
a Discounted at 4 %
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costly LAI. Moreover, paliperidone LAI remained the
dominant strategy versus aripiprazole LAI, olanzapine LAI
and haloperidol LAI in terms of cost per QALY gained and
continued to dominate risperidone LAI, aripiprazole LAI
and haloperidol LAI in terms of cost per relapses avoided.
When assuming 1 additional week of hospitalisation
after 1 month of stabilisation for all LAIs, the conclusions
remained the same (i.e. paliperidone LAI dominated all the
other LAIs except risperidone LAI in terms of QALYs, and
paliperidone LAI dominated all the other LAIs except
olanzapine LAI in terms of relapses).
Conclusions were also unchanged when increasing the
monthly paliperidone LAI dose from 75 to 100 mg (i.e.
monthly costs from €250.7 to €306.9).
Assuming similar utility values between the health states
‘Relapse without hospitalisation’ and ‘Relapse with hos-
pitalisation’ (instead of using the average utility between
‘Stable’ and ‘Relapse with hospitalisation’) caused only a
minor impact on the results and did not modify the
conclusion (i.e. ICER of paliperidone LAI vs. olanzapine
oral of €2368 per QALY instead of €2411 per QALY in the
base case, and ICER of risperidone LAI vs. oral olanzapine
of €4,936,304 per QALYs instead €4,770,018 per QALY in
the base case).
Finally, in the scenario in which the diabetes incidence
rates for all comparators were set up to the paliperidone
LAI rate (i.e. 0.55 %), aripiprazole LAI was associated
with a slightly higher number of QALYs compared with
paliperidone LAI (i.e. ?0.003 QALYs gained for arip-
iprazole LAI vs. paliperidone LAI) and with an ICER of
€1,5136,483 versus paliperidone LAI. The other conclu-
sions were similar to those for the base-case analysis.
3.2.3 Probabilistic Sensitivity Analysis
We conducted PSAs with 10,000 iterations. The incre-
mental costs and effects of paliperidone LAI versus all
other comparators (i.e. risperidone LAI, aripiprazole LAI,
Fig. 3 Efficiency frontier in
terms of quality-adjusted life-










Table 8 Results of the base case; ICER (€ per QALY gained and relapse avoided) per patient and per treatment over 5 years
Discounted costsa (€) Discounted QALYsa Discounted relapsesa ICER/QALY gained ICER/relapse avoided
OO 50,379 3.5558 1.7175
PLAI 50,880 3.7634 1.4366 €2411 €1782
RLAI 54,952 3.7642 1.4387 €4,770,018 Dominated
HLAI 55,127 3.6227 1.8046 Dominated Dominated
ALAI 55,657 3.7549 1.4648 Dominated Dominated
OLAI 55,843 3.5753 1.4333 Dominated €1,529,377
Strategies were sorted by descending costs to exclude dominated strategies (i.e. more costly and less effective) and extendedly dominated
strategies. The ICERs were then computed between two consecutive strategies, which have not been excluded
ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, ICER incremental cost-effectiveness ratio, OLAI olanzapine
long-acting injectable, OO oral olanzapine, PLAI paliperidone long-acting injectable, QALY quality-adjusted life-year, RLAI risperidone long-
acting injectable
a Discounted at 4 %
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olanzapine LAI, haloperidol and oral olanzapine) for each
simulation were reported on a cost-effectiveness plane
(Fig. 5). The multiple comparison analyses on the cost-
effectiveness plane enabled a simultaneous assessment of
all the treatment options. However, the presentation of the
cost-effectiveness results is more complex than in pairwise
comparisons [60]. The optimal strategy is identified as the
strategy associated with the highest net monetary benefit
(NMB)7 below the maximum willingness to pay (WTP) for
an extra QALY gained (or relapse avoided). Overall,
paliperidone LAI generated more QALYs and was less
costly than other comparators. When making pairwise
comparisons, paliperidone LAI was dominant in terms of
QALYs gained (i.e. more effective and less costly) in more
than 64 % of the 10,000 simulations for each comparator,
except versus risperidone LAI (41.76 %). As stated in a
recent report from the HAS, France has no official
threshold of a maximum WTP for an additional QALY
[61]. An estimated range based on published data was
provided as example (i.e. between €1811 and €54,612).
Other examples can be identified in the literature, for
instance, Deconinck et al. used a threshold of €50,000 per
QALY in a French study in oncology [62]. Thus, to follow
a conservative approach, results are presented here using
thresholds lower than €30,000.
Above a threshold of €8000 per QALY gained, the
acceptability curve showed that paliperidone LAI had a
probability[50 % to be identified as the optimal strategy
in comparison with all other strategies simultaneously in
terms of QALYs gained (Fig. 6).
In terms of cost per relapse avoided, the cost-effec-
tiveness plane showed a linear relationship between
paliperidone LAI and each comparator, which could be
explained by the high correlation between relapse and
hospitalisation (Fig. 7). Head-to-head comparisons showed
that paliperidone LAI was strongly dominant in more than
50 % of the simulations when compared with each com-
parator except olanzapine LAI (i.e. the probability for
paliperidone LAI of dominating olanzapine LAI was
47.30 %). At a threshold lower than €30,000, the accept-
ability curve showed that paliperidone LAI was likely to be
cost effective in more than 40 % of the simulations com-
pared with all other strategies simultaneously (Fig. 8).
4 Discussion
Schizophrenia is a disabling mental disorder characterised
by remission phases and relapse episodes. These relapse
episodes can often lead to hospitalisation and have a sig-
nificant impact on the burden of disease [45]. LAI
administration tends to improve patient compliance and is
therefore recommended in the prevention of relapses [12].
The present study, to the best of our knowledge, is the
first model to use real-life French hospitalisation data to
estimate the efficacy of antipsychotics [26] with the sin-
gularity to distinguish initiation and prevention phases.
Several health economic models in schizophrenia have
been developed [28, 29, 63, 64], but only one study
assessing the cost effectiveness of different antipsychotics
in France has been identified [30]. In 2005, Llorca et al.
[25] evaluated the impact in terms of medical benefits and
costs of risperidone LAI, haloperidol LAI or oral olanza-
pine over a 2-year time horizon. To consider the advan-
tages of LAIs (e.g. better compliance), several hypotheses
Fig. 4 Efficiency frontier in









7 NMB = effectiveness 9 WTP - cost.
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Fig. 5 Cost-effectiveness plane
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Fig. 7 Cost-effectiveness plane
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were made, including the success rate (i.e. patient on the
same antipsychotic treatment over 2 years) was increased
by 5 % for first-generation LAI antipsychotics and by 10 %
for second-generation LAI antipsychotics compared with
an oral equivalent, while the efficacy of oral olanzapine
was unchanged. The study showed that risperidone LAI
was associated with the greatest proportion of responders
and the lowest cost (82.70 %; €14,055), followed by oral
olanzapine (75.80 %; €14,351) and haloperidol LAI
(57.30 %; €17,203). In comparison, our model concluded
that oral olanzapine was the least costly strategy (€21,124;
year 2014 undiscounted costs), followed by haloperidol
LAI (€26,184) and risperidone LAI (€26,687) at a 2-year
time horizon. However, at a 5-year time horizon, our model
concluded that risperidone LAI becomes less costly than
haloperidol LAI. If we assume that relapses avoided rep-
resent treatment success, our results are consistent with
those found by Llorca et al. [25] (i.e. risperidone LAI was
associated with the lowest number of relapses, followed by
oral olanzapine and haloperidol LAI, at a 2-year time
horizon).
Our model estimated an average annual cost of
approximatively €11,500 associated with the healthcare
management of a patient with schizophrenia, compared
with average costs of €7500 in the publication from 2005.8
The cost difference can be explained first by the inclusion
of three additional adverse effects (i.e. TD, diabetes and
WG) and second by the distinction between the two phases
in our model, which allowed a better estimate of the costs
associated with the initiation of a treatment. For compar-
ison, in 2014 the French Ministry of Health estimated the
average cost of therapeutic management of schizophrenia
in France to be approximately €15,000 [7].
Six analyses assessing the cost effectiveness of
paliperidone LAI have been identified in other countries:
Mehnert et al. [28] in Sweden, Zeidler et al. [29] in Ger-
many, Kolek et al. [64] in the Czech Republic, Einarson
et al. [63] in Finland, Citrome et al. [65] in the USA and
Lee et al. in Wales [23].
The first three models were based on the same Markov
model structure (i.e. Mehnert et al. [28]). The Swedish
analysis showed that paliperidone LAI dominated risperi-
done LAI and olanzapine LAI over a 5-year time horizon
[28]. In the German study, paliperidone LAI dominated
risperidone LAI. However, paliperidone LAI was associ-
ated with an ICER of €748/QALY gained and €278/avoi-
ded relapse compared with olanzapine LAI [29]. The
model in the study from the Czech Republic showed that
paliperidone LAI was cost effective from the payer’s per-
spective and was associated with an ICER of €16,233/
QALY gained when compared with oral risperidone [64].
Results of our analysis differed from those of the Swedish
and the German models, partly due to input parameters and
the health organisation system. In the present model, effi-
cacy data were based on real-life hospitalisation rates
whilst efficacy inputs were weighted by compliance ratios
in the other studies. Moreover, mean hospitalisation dura-
tion varied across studies, with 66.4 days in Mehnert et al.
[28] and 33.7 days in Zeidler et al. [29], when they were
time dependent based on real data in our analysis (i.e.
Fig. 8 Cost-effectiveness
acceptability curve in terms of









8 The unweighted average cost after 1 year of long-acting risperi-
done, oral olanzapine and haloperidol decanoate are provided here for
information only, and thus must be interpreted with caution.
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assuming 85 % of patients in relapse leaving hospital
within 3 months, 10 % at 3–6 months, 2 % at 6–9 months,
1 % at 9–12 months and 2 % after 12 months; see
Appendix Table 11).
The Finnish study assessed paliperidone LAI, risperi-
done LAI and olanzapine LAI in patients switched to LAI
antipsychotics due to compliance issues with previous
treatments [63]. At the 1-year time horizon, paliperidone
LAI was associated with better outcomes and was less
costly than risperidone LAI and olanzapine LAI. However,
the heterogeneity of input parameter sources may be con-
sidered a limitation, i.e. risperidone LAI data were based
on an observational study conducted in Spain [66], while
olanzapine LAI inputs were derived from a real-life study
performed in the USA [67] and an international clinical
trial [68].
Finally, the Welsh analysis compared the cost effec-
tiveness of paliperidone LAI versus risperidone LAI, and
the authors concluded that paliperidone LAI dominated
risperidone LAI in terms of QALYS gained [23]. The
relative incremental discounted costs and incremental
discounted QALYs after 10 years between the two
treatments was –2.90 % (paliperidone LAI less costly
than risperidone LAI) and 2.83 % (paliperidone LAI
associated with more QALYs than risperidone LAI),
respectively. In our model, after 5 years, the relative
incremental discounted costs and QALYs of paliperi-
done LAI versus risperidone LAI were -7.41 and -
0.02 %, respectively. It could be noted that the Welsh
model assumed a higher utility for paliperidone LAI than
for risperidone LAI in the remission state in order to take
into consideration the lower frequency of injections
associated with paliperidone LAI (i.e. utility decrement
associated with pain at the injection site). Based on
French expert opinion, we decided there was not enough
clinical evidence to use such a disutility in the French
context.
A recent cost-effectiveness analysis was conducted in
the USA to assess the efficiency of aripiprazole LAI versus
paliperidone LAI in various dosing scenarios [65]. Overall,
results were in favour of aripiprazole LAI, as it was asso-
ciated with fewer relapses at lower costs or a reasonable
cost-effectiveness threshold compared with paliperidone
LAI at the 1-year time horizon. Nevertheless, efficacy and
safety parameters were derived from product prescribing
information and pivotal trials, which could introduce biases
in the results caused by targeted population heterogeneity
and lack of adjustment of the treatment on the placebo
arms.
A systematic literature review of cost-effectiveness
analyses in LAI antipsychotics was conducted by Achilla
and McCrone in 2013 [69]. Of the 154 records screened,
28 studies were included in the review. Heterogeneity in
terms of outcomes such as data sources used for costs
and resources and study durations made the comparison
between countries and studies difficult. However, with
the exclusion of studies that were not directly compa-
rable, the authors concluded that paliperidone extended-
release was the most cost-effective option compared
with other oral second-generation or first-generation LAI
antipsychotics. It was also reported that generally, long-
acting second-generation antipsychotics (especially
risperidone) were cost effective versus long-acting
haloperidol and other oral or depot formulations as first-
line treatments.
Given the heterogeneity between studies, our results in
terms of costs, relapses and QALYs were generally in line
with previous analyses and were validated by experts.
4.1 Limitations
Our study was subject to some limitations due to the
assumptions applied to the model when data were not
available. Beyond missing data, the main limitations to
highlight are the heterogeneity of clinical practice in
schizophrenia and the hospitalisation cost with no clear
accepted reference in France.
Due to a lack of data, the model does not enable
assessment of treatment effects at an individual level (e.g.
level of compliance according to age, year since diagnosis,
patient history, etc.). However, a cohort approach seems to
be a reasonable choice to accurately assess the global
incremental impacts between antipsychotics, with the
reserve of potential bias due to the heterogeneity of
patient’s characteristics in real life.
In our model, we assumed that patients were treated
with antipsychotic monotherapy in order to focus on the
effect of studied antipsychotics. In reality, 30 % of patients
with schizophrenia are managed with antipsychotic com-
bination therapy [70]. Compliance with treatment is diffi-
cult to capture and quantify; moreover, data in France were
scarce, so hospitalisation rates were used to derive the risk
of relapse based on CGS [26]. However, it has been shown
that hospitalisation is the best proxy for relapses for
patients with schizophrenia, and real-life data ensure
robustness to parameter values used in the model [26, 45].
Although doses were derived from SmPCs, they may not
always reflect doctor’s prescriptions, and the average
monthly dose for paliperidone LAI may be higher in real
life. However, paliperidone LAI monthly dose was
increased to 100 mg in the sensitivity scenario, and
paliperidone LAI remained the less costly LAI.
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Data focusing on France to populate the model were
limited, especially for recently approved drugs (such as
aripiprazole LAI, approved in 2013 [71]) leading to the
need for several assumptions. In this context, proportions
of adverse events were partly based on ranges provided
in SmPCs. Mid-points between the highest and the
lowest interval limits were applied. Proportions of
adverse events were consistent with clinical practice,
although the proportion of diabetes associated with
aripiprazole LAI was discussed (i.e. 1 % per cycle in our
model, based on a conservative approach using the lower
bound of the range from 1/100 to 1/10 [34]). However, it
was considered the most reliable source based on expert
opinion and was tested in sensitivity analysis. Another
limitation due to lack of data was that the model
assumed similar and constant probabilities of treatment
discontinuation regardless of treatment line and time. In
clinical practice, patients with prior relapse have a
greater probability of relapse than stable patients without
relapse, while patients stable after 1 year of treatment
have a reduced probability of relapse or switch due to
lack of tolerance. Thus, and according to clinical
experts1, our analysis may underestimate the proportion
of patients continuing to receive initial treatment over
time compared with real life. However, the evolution of
this proportion was consistent with previous analyses
when considering similar time-independent transition
assumptions [23, 28]. Probabilities of leaving the hospital
during a relapse episode were derived from real-life data
from one hospital centre and may not be representative
of all centres in France. It was assumed that EPS events
lasted for one cycle of 3 months. Patients faced the same
probability of experiencing an EPS event at each cycle
regardless of his/her previous EPS event sequence (due
to memoryless Markov property), and thus EPS events
may have been overestimated. The maintenance cost of
schizophrenia was based on an aggregated cost from the
SHI database. This cost was applied to stable patients
without adverse events, and additional costs have been
associated with adverse events. Thus, maintenance cost
may also be overestimated.
Finally, it should be noted that, although validation of
the model by external reviewers would have strengthened
the study methods, limited time and resources precluded
this. However, extensive PSAs were performed. These
analyses aimed to assess the impact of uncertain input
parameters and assumptions (mentioned above) on model
results. PSA showed that results in terms of QALYs were
robust, with paliperidone LAI as optimal strategy in more
than 50 % of cases for a threshold of WTP above €8000
per QALY gained.
5 Conclusions
The present analysis highlighted that paliperidone LAI is a
relevant option in the treatment of patients with
schizophrenia. Using an original model based on original
observational data provides additional information to sup-
port decision choice in the management of schizophrenia in
France. This study also highlighted the scarcity of available
data, especially on long-term efficacy. Observational
studies should be conducted in order to validate theoretical
results presented in this study.
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Technical Appendix
See Tables 9, 10, 11 and 12.
Table 9 HAS guidelines for French economic evaluation studies [26]
Reference case analysis Status
The method of evaluation CUA or CEA according to the nature of the health effects
of the intervention
Required reference
If HR-QOL is an important consequence, a CUA is used Required reference
If health-related HR-QOL is not an important
consequence, a CEA is used
Perspective Collective perspective Required reference
On costs All healthcare funders
On health effects Population whose health is affected (identification and
measurement of health effects) and general public
(preference-based scores)
Population analysed All the individuals concerned, directly or indirectly Preferred reference
Intervention comparators All interventions competing with the intervention studied
are identified
Required reference
The choice of interventions included as comparator is the
responsibility of the author, and is justified
Time horizon A time horizon long enough to reflect all expected
differences in costs and health effects
Required reference
Discount rate Discounting is done at the public discount rate. It stood at
4 % at the time of writing this guide and views the
relative price of the health effects to the community as
being invariable over time
Required reference
After 30 years, the discount rate linearly declines to 2 %
Summary of data Based on a systematic and critical review of clinical and
economic studies
Required reference
Based on data from all relevant studies, subject to their
ability to limit bias and to consider ‘real-life’ practice
Required reference
French data Preferred reference
Heath outcome criteria QALYs in CUAs Required reference
Life-years in CEAs Preferred reference
Costs criteria Production costs Required reference
Conclusions of health
economic evaluation
Efficiency frontier and calculation of an ICER for non-
dominated interventions
Required reference





Analysis of variability and uncertainty, whatever the source Required reference
Discussion of the conclusions and limitations of the
evaluation
Required reference
Reference case analysis defines the features of health economic evaluation at HAS and the recommended methodology for each component of an
analysis. It distinguishes between ‘‘required’’ references, to which the author must strictly comply, and ‘‘preferred’’ references, which allow the
use of a different method when this is clearly justified
CUA cost-utility analysis, CEA cost-effectiveness analysis, HR-QOL health-related quality of life, ICER incremental cost-effectiveness ratio,
QALY quality-adjusted life-year
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Table 10 One-way sensitivity analysis: input parameters
Items Minimuma (%) Maximuma (%)
Discount rate -15 ?15
Age at baseline -15 ?15
Proportion of male -15 ?15
SMR -15 ?15
Probability of interruption (due to patient choice, lost to follow up and other reasons) -15 ?15
Probability of relapse (due to lack of efficacy) -15 ?15
Probability of switch (due to lack of tolerance) -15 ?15
Adverse events -15 ?15
Initiation of a new antipsychotic (except clozapine) without relapse – outpatient 90.0 100.0
Initiation of a new antipsychotics without relapse – outpatient 0.0 20.0
Hospitalisation cost -15 ?15
Maintenance cost -15 ?15
Utility scores (health states) -15 ?15
Utility decrement (adverse events) -15 ?15
SMR standardised mortality rate
a Minimums and maximums based on expert opinions
Table 11 Probabilistic sensitivity analysis: input parameters and distributions
Input parameters Distribution PSA parameters Comments
Mortality data Median ET l r
SMR (median): stable: male Log-normal 3.02 0.15 1.1 0.1 Hypothesis: SD = 10 % 9 mean
SMR (median): stable: female Log-normal 2.37 0.12 0.9 0.1 Hypothesis: SD = 10 % 9mean
SMR median: relapse Log-normal 6.20 0.32 1.8 0.1 Hypothesis: SD = 10 % 9mean
Treatment sequences
First line: % of pts initiating AP1 at the hospital Min Max a b
PLAI Uniform 80 % 100 % 0.8 1.0
RLAI Uniform 80 % 100 % 0.8 1.0
ALAI Uniform 80 % 100 % 0.8 1.0
OLAI Uniform 80 % 100 % 0.8 1.0
HLAI Uniform 80 % 100 % 0.8 1.0
OO Uniform 00 % 20 % 0.0 0.2
Second line Mean Var aj b = 1
After PLAI
PLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
RLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
ALAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
OLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
After RLAI
PLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
RLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
ALAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
OLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
After ALAI
PLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
RLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
ALAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
OLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
Antipsychotics in Schizophrenia in France 381
Table 11 continued
Input parameters Distribution PSA parameters Comments
After OLAI
PLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
RLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
ALAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
OLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
After HLAI
PLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
RLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
ALAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
OLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
After OO
PLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
RLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
ALAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
OLAI Dirichlet 25 % 0.25 % 25.0 1.0 Hypothesis: Var = mean/100
Probabilities of interruption
Probabilities of interruption and being stable at
3 months
Events Pop. a b
PLAI: initiation Beta 88 607 88 519
PLAI: prevention Beta 28 206 28 178
Events Pop. a b
RLAI: initiation Beta 89 613 89 524
RLAI: prevention Beta 28 206 89 178
Mean Variance a b
ALAI: initiation Beta 0.1767 0.0004 70.11 326.67
Events Pop. a b
ALAI: prevention Beta 28 206 28 178
Mean Variance a b
OLAI: initiation Beta 0.1412 0.0002 96.24 585.15
Events Pop. a b
OLAI: prevention Beta 28 206 28 178
Mean Variance a b
HLAI: initiation Beta 0.2203 0.0004 98.79 349.57
Events Pop. a b
HLAI: prevention Beta 28 206 28 178
Mean Variance a b
OO: initiation Beta 0.1412 0.0002 96.24 585.15
Events Pop. a b
OO: prevention Beta 28 206 28 178
Transition probabilities of stable pts Mean Variance aj b = 1
1. Probability of being
stable without treatment
Dirichlet 0.2307 0.0023 23.07 1 Hypothesis: Var = mean/100




Dirichlet 0.2307 0.0023 23.07 1 Hypothesis: Var = mean/100
3. Probability of initiating a
new antipsychotic
Dirichlet 0.2307 0.0023 23.07 1 Hypothesis: Var = mean/100
Mean Variance a b
382 S. Druais et al.
Table 11 continued
Input parameters Distribution PSA parameters Comments
4. Median time before
relapse
Gamma 172 25.5 45.5 3.8
Probabilities of relapse
Probabilities of relapse at 3 months Events Pop. a b
PLAI: initiation Beta 40 607 40 567
Moy/an Var/an a b
PLAI: prevention Beta 0.2915 0.0163 3.4092 8.2855
Mean Pop. a b
RLAI: initiation Beta 43 613 43 570
Mean/year Var/an a b
RLAI: prevention Beta 0.2915 0.0163 3.4092 8.2855
Mean Variance a b
ALAI: initiation Beta 0.0820 0.0001 62.336 698.06
Mean/year Var/an a b
ALAI: prevention Beta 0.2915 0.0163 3.4092 8.2855
Mean Variance a b
OLAI: initiation Beta 0.0640 0.000 87.937 1285.1
Mean/year Var/an a b
OLAI: prevention Beta 0.2915 0.0163 3.4092 8.2855
Mean Variance a b
HLAI: initiation Beta 0.1052 0.0001 85.501 727.18
Mean RR Var RR a b
HLAI: prevention Beta 0.5300 0.0115 10.971 9.7287
Mean Variance a b
OO: initiation Beta 0.0640 0.000 87.937 1285.1
Mean RR Var RR a b
OO: prevention Beta 0.6000 0.0183 7.2774 4.8516
Proportions of pts in relapse leaving the hospital Mean Variance aj b = 1
Within the 3 months Dirichlet 0.8493 0.0009 84.9315 1
Between 3 and 6 months Dirichlet 0.1027 0.0006 10.274 1
Between 6 and 9 months Dirichlet 0.0205 0.0001 2.0548 1
Between 9 and 12 months Dirichlet 0.0068 0.000 0.6849 1
After 12 months Dirichlet 0.0205 0.0001 2.0548 1
Proportion of relapse requiring a hospitalisation Mean Variance a b
% hospitalised patients Beta 0.6700 0.0012 126.10 62.110 Hypothesis: SD = 10 %*Mean
Proportion of pts treated by the same antipsychotic than
the previous line after a relapse
Mean Variance a b
% of patients initiating the
same antipsychotic
Beta 0.1500 0.0001 326.39 1849.5 Hypothesis: SD = 10 %*Mean
Probabilities of switch (due to lack of tolerance)
Probabilities of switch at 3 months Events Pop. a b
PLAI: initiation Beta 20 607 20 587
PLAI: prevention Beta 3 206 3 203
Events Pop. a b
RLAI: initiation Beta 10 613 10 603
RLAI: prevention Beta 3 206 3 203
Mean Variance a b
ALAI: initiation Beta 0.0413 0.000 59.435 1378.1
Events Pop. a b
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Table 11 continued
Input parameters Distribution PSA parameters Comments
ALAI: prevention Beta 3 206 3 203
Mean Variance a B
OLAI: initiation Beta 0.0320 0.0000 84.855 2567.5
Events Pop. a b
OLAI: prevention Beta 3 206 3 203
Mean Variance a b
HLAI: initiation Beta 0.0537 0.000 80.547 1418.4
Events Pop. a b
HLAI: prevention Beta 3 206 3 203
Mean Variance a b
OO: initiation Beta 0.0320 0.0000 84.855 2567.5
Events Pop. a b
OO: prevention Beta 3 206 3 203
Adverse events
Extrapyramidal syndrome (3-monthly probabilities)
Initiation and prevention
phases
Events Pop. a b
PLAI Beta 55 1000 55 945
RLAI Beta 55 1000 55 945
Mean Variance a b
ALAI Beta 0.0353 0.0001 8.6805 237.14
OLAI Beta 0.0321 0.0001 17.849 538.03
HLAI Beta 0.1328 0.0007 20.496 133.82
OO Beta 0.0321 0.0001 17.849 538.03
Clozapine Beta 0.0098 0.000 4.1602 420.47
Tardive dyskinesia (3-monthly probabilities)
Initiation phase Events Pop. a b
PLAI Beta 1 606 1 605
RLAI Beta 1 608 1 607
ALAI Beta 1 606 1 605
OLAI Beta 0 234 0 234
HLAI Beta 5 219 5 214
OO Beta 0 234 0 234
Clozapine Beta 0 234 0 234
Prevention phase Min Max a b
PLAI Uniform 0.0010 0.0100 0.0010 0.0100
RLAI Uniform 0.0010 0.0100 0.0010 0.0100
ALAI Uniform 0.0010 0.0100 0.0010 0.0100
OLAI Uniform 0.0010 0.0100 0.0010 0.0100
HLAI Uniform 0.0100 0.1000 0.0100 0.1000
OO Uniform 0.0010 0.0100 0.0010 0.0100
Clozapine Uniform 0.0000 0.0001 0.0000 0.0001
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Table 11 continued
Input parameters Distribution PSA parameters Comments
Diabetes (3-monthly probabilities)
Prevention phase Min Max a b
PLAI Uniform 0.0010 0.0100 0.0010 0.0100 Hypothesis: ranges of the SmPC
used for all treatments with
an uniform distribution
RLAI Uniform 0.0010 0.0100 0.0010 0.0100
ALAI Uniform 0.0100 0.1000 0.0100 0.100
OLAI Uniform 0.0010 0.0100 0.0010 0.0100
HLAI Uniform 0.0010 0.0100 0.0010 0.0100
OO Uniform 0.0010 0.0100 0.0010 0.0100
Clozapine Uniform 0.0001 0.0010 0.0001 0.0010
Weight gained (3-monthly probabilities)
Initiation phase Events Pop. a b
PLAI Beta 55 1000 55 945
RLAI Beta 55 1000 55 945
ALAI Beta 55 1000 55 945
Mean Variance a b
OLAI Beta 0.4680 0.0006 203.905 231.79
Events Pop. a b
HLAI Beta 55 1000 55 945
Mean Variance a b
OO Beta 0.4680 0.0006 203.905 231.79
Events Pop. a b
Clozapine Beta 55 1000 55 945
Prevention phase Min Max a b
PLAI Uniform 0.0100 0.1000 0.0100 0.1000
RLAI Uniform 0.0100 0.1000 0.0100 0.1000
ALAI Uniform 0.0100 0.1000 0.0100 0.1000
OLAI Uniform 0.1000 1.0000 0.1000 1.0000
HLAI Uniform 0.0100 0.1000 0.0100 0.1000
OO Uniform 0.0100 0.1000 0.0100 0.1000
Clozapine Uniform 0.0100 0.1000 0.0100 0.1000
Costs and resources
Initiation of a new treatment in case of interruption or switch (relapse excluded)
PLAI, RLAI, ALAI, OLAI,
HLAI, OO
Mean Variance a b
Outpatient care Beta 0.9000 0.0021 37.5160 4.1684
Clozapine Mean Variance a b
Outpatient care Beta 0.1000 0.000 645.644 3110.80
Number of hospitalised weeks required after the
stabilisation phase for the initiation of each
antipsychotic
Min Max a b
PLAI Triangular -1 1 0 2
RLAI Triangular -1 1 1 3
ALAI Triangular -1 1 1 3
OLAI Triangular -1 1 1 3
HLAI Triangular -1 1 0 2
OO Triangular -1 1 0 1
Clozapine Triangular -1 1 0 1
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Table 11 continued
Input parameters Distribution PSA parameters Comments
Hospitalisation cost (1 day) Min (- %) Max (? %) a b
Initiation phase Triangular -1 1 218 655
Relapse Triangular -1 1 218 655
Mean duration of stabilisation (days) at the hospital Mean r a b
Within 3 months Trunc.normal 30 33 0 90 Hypothesis:
Between 3 and 6 months Trunc.normal 135 33 90 180
Between 6 and 9 months Trunc.normal 225 33 180 270
Between 9 and 12 months Trunc.normal 315 33 270 360
After 12 months Trunc.normal 715 240 360 1800
Maintenance costs: outpatient care Min (- %) Max (? %) a b
Annual cost Triangular -1 1 531 1592
Additional psychiatrist visits Min Max a b
Initiation phase Triangular -1 1 5 7
Relapse Triangular -1 1 5 7
Resources and costs associated with adverse events
Extrapyramidal syndrome Min Max a b
GP Triangular -1 1 0 2
Psychiatrist Triangular -1 1 0 2
Tardive dyskinesia Min Max a B
GP Triangular -1 1 0 2
Psychiatrist Triangular -1 1 0 2
Neurologist Triangular -1 1 0 2
Diabetes Min (- %) Max (? %) a b
Global cost (3 months) Triangular -1 1 659 1977
Weight gained Min Max a b
GP Triangular -1 1 0 2
Psychiatrist Triangular -1 1 0 2
Nutritionist Triangular -1 1 0 2
Endocrinologist Triangular -1 1 0 2
Blood glucose analysis Triangular -1 1 0 2
Lipid abnormality
investigations
Triangular -1 1 0 2
Utility data
Utility data by health states Mean SD l r
Stable (without adverse
events)
Log-normal 0.23 0.01 -1.57 0.45 Hypothesis: SD = 10 % 9 mean
Relapse (without
hospitalisation)
Log-normal 0.19 0.01 -1.78 0.49 Hypothesis: SD = 10 % 9 mean
Relapse (requiring
hospitalisation)
Log-normal 0.15 0.01 -2.04 0.54 Hypothesis: SD = 10 % 9 mean
Utility decrement by adverse events Mean SD l r
Extrapyramidal syndrome Log-normal 0.0493 0.0025 -3.3663 0.8432 Hypothesis: SD = 10 % 9 mean
Tardive dyskinesia Log-normal 0.0493 0.0025 -3.3663 0.8432 Hypothesis: SD = 10 % 9 mean
Diabetes Log-normal 0.0375 0.0019 -3.7129 0.9268 Hypothesis: SD = 10 % 9 mean
Weight gained Log-normal 0.0235 0.0012 -4.3278 1.0743 Hypothesis: SD = 10 % 9 mean
ALAI aripiprazole long-acting injectable, AP antipsychotic first-line, HLAI haloperidol long-acting injectable, Max maximum, Min minimum,
OLAI olanzapine long-acting injectable, OO oral olanzapine, PLAI paliperidone long-acting injectable, Pop population, PSA probabilistic
sensitivity analysis, pts patients, RLAI risperidone long-acting injectable, SD standard deviation, SMR standardised mortality rate, Var variance
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Costs by cycle €4040 €1039 €265 €21,251 €29,174 €32,931 €268,658 €1601
Distribution by cost category
Medication 12.41 % 72.42 % 0.00 % 1.19 % 0.49 % 0.27 % 0.00 % 68.08 %
Administration 0.35 % 2.02 % 0.00 % 0.03 % 0.01 % 0.01 % 0.00 % 1.47 %
Tests 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Hospitalisation 75.68 % 0.00 % 0.00 % 97.67 % 99.01 % 99.48 % 100.00 % 0.00 %
Consultation 5.49 % 0.00 % 0.00 % 0.52 % 0.25 % 0.11 % 0.00 % 13.87 %
Maintenance 6.06 % 25.55 % 100.00 % 0.58 % 0.24 % 0.13 % 0.00 % 16.58 %
RLAI
Total costs €7084 €1093 €265 €21,679 €29,500 €33,140 €268,658 €1534
Distribution by cost category
Medication 7.49 % 71.86 % 0.00 % 1.32 % 0.54 % 0.30 % 0.00 % 66.55 %
Administration 0.40 % 3.84 % 0.00 % 0.07 % 0.03 % 0.02 % 0.00 % 1.67 %
Tests 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Hospitalisation 86.34 % 0.00 % 0.00 % 97.54 % 98.97 % 99.44 % 100.00 % 0.00 %
Consultation 2.61 % 0.00 % 0.00 % 0.51 % 0.23 % 0.11 % 0.00 % 14.47 %
Maintenance 3.17 % 24.29 % 100.00 % 0.56 % 0.23 % 0.13 % 0.00 % 17.30 %
ALAI
Total costs €7076 €1092 €265 €21,675 €29,498 €33,139 €268,658 €1538
Distribution by cost category
Medication 7.59 % 73.77 % 0.00 % 1.34 % 0.55 % 0.31 % 0.00 % 66.84 %
Administration 0.20 % 1.92 % 0.00 % 0.03 % 0.01 % 0.01 % 0.00 % 1.46 %
Tests 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Hospitalisation 86.43 % 0.00 % 0.00 % 97.55 % 98.98 % 99.45 % 100.00 % 0.00 %
Consultation 2.61 % 0.00 % 0.00 % 0.51 % 0.23 % 0.11 % 0.00 % 14.44 %
Maintenance 3.17 % 24.30 % 100.00 % 0.56 % 0.23 % 0.13 % 0.00 % 17.26 %
OLAI
Total costs €4399 €1576 €265 €21,433 €29,276 €32,995 €268,658 €1603
Distribution by cost category
Medication 19.86 % 83.16 % 0.00 % 2.06 % 0.85 % 0.47 % 0.00 % 68.39 %
Administration 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 1.21 %
Tests 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Hospitalisation 69.52 % 0.00 % 0.00 % 96.84 % 98.66 % 99.28 % 100.00 % 0.00 %
Consultation 5.05 % 0.00 % 0.00 % 0.52 % 0.25 % 0.11 % 0.00 % 13.85 %
Maintenance 5.57 % 16.84 % 100.00 % 0.58 % 0.24 % 0.13 % 0.00 % 16.55 %
HLAI
Total costs €3581 €336 €265 €21,019 €29,043 €32,849 €268,658 €1417
Distribution by cost category
Medication 1.38 % 14.76 % 0.00 % 0.12 % 0.05 % 0.03 % 0.00 % 64.02 %
Administration 0.20 % 6.25 % 0.00 % 0.02 % 0.01 % 0.00 % 0.00 % 1.59 %
Tests 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Hospitalisation 85.38 % 0.00 % 0.00 % 98.75 % 99.45 % 99.72 % 100.00 % 0.00 %
Consultation 6.20 % 0.00 % 0.00 % 0.53 % 0.25 % 0.11 % 0.00 % 15.66 %
Maintenance 6.84 % 78.99 % 100.00 % 0.59 % 0.24 % 0.13 % 0.00 % 18.73 %
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Total costs €628 €406 €265 €20,604 €28,717 €32,644 €268,658 €1428
Distribution by cost category
Medication 22.40 % 34.65 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 64.51 %
Administration 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 1.35 %
Tests 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
Hospitalisation 0.00 % 0.00 % 0.00 % 98.85 % 99.49 % 99.75 % 100.00 % 0.00 %
Consultation 35.34 % 0.00 % 0.00 % 0.54 % 0.26 % 0.11 % 0.00 % 15.55 %
Maintenance 42.25 % 65.35 % 100.00 % 0.61 % 0.25 % 0.14 % 0.00 % 18.59 %
2nd line
Total costs €1977 €1200 €265 €18,286 €26,810 €31,478 €268,744 €858
Distribution by cost category
Medication 51.29 % 76.13 % 0.00 % 1.62 % 0.66 % 0.35 % 0.00 % 32.69 %
Administration 1.11 % 1.75 % 0.00 % 0.05 % 0.02 % 0.01 % 0.00 % 0.40 %
Tests 0.00 % 0.00 % 0.00 % 0.47 % 0.32 % 0.27 % 0.03 % 10.09 %
Hospitalisation 23.20 % 0.00 % 0.00 % 96.46 % 98.40 % 99.07 % 99.97 % 0.00 %
Consultation 11.14 % 0.00 % 0.00 % 0.61 % 0.28 % 0.12 % 0.00 % 25.88 %
Maintenance 13.27 % 22.12 % 100.00 % 0.79 % 0.32 % 0.17 % 0.00 % 30.94 %
3rd line (clozapine)
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